Merck & Co Inc (MRK)

MRK (NYSE:Drugs) EQUITY
$57.67
pos +0.07
+0.12%
Today's Range: 57.50 - 58.33 | MRK Avg Daily Volume: 10,623,900
Last Update: 07/02/15 - 4:00 PM EDT
Volume: 8,518,380
YTD Performance: 1.55%
Open: $57.96
Previous Close: $57.60
52 Week Range: $52.49 - $63.62
Oustanding Shares: 2,825,221,749
Market Cap: 162,732,772,742
6-Month Chart
TheStreet Ratings Grade for MRK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 6 6
Moderate Buy 0 0 0 0
Hold 7 6 6 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.08 2.00 2.00 2.08
Latest Dividend: 0.45
Latest Dividend Yield: 3.12%
Dividend Ex-Date: 06/11/15
Price Earnings Ratio: 15.04
Price Earnings Comparisons:
MRK Sector Avg. S&P 500
15.04 15.10 26.13
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
1.00% -2.34% 37.80%
GROWTH 12 Mo 3 Yr CAGR
Revenue -4.10 -0.12 -0.04
Net Income 164.20 0.87 0.23
EPS 176.90 1.02 0.26
Earnings for MRK:
EBITDA 13.37B
Revenue 42.24B
Average Earnings Estimates
Qtr (06/15) Qtr (09/15) FY (12/15) FY (12/16)
Average Estimate $0.80 $0.89 $3.44 $3.82
Number of Analysts 8 7 11 12
High Estimate $0.84 $0.93 $3.47 $3.97
Low Estimate $0.74 $0.83 $3.40 $3.56
Prior Year $0.85 $0.90 $3.49 $3.44
Growth Rate (Year over Year) -5.88% -1.11% -1.41% 11.02%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Ophir Gottlieb

 | Jul 2, 2015 | 11:00 AM EDT

It's almost impossible to get too excited about its success.

By

Roger Arnold

 | Jun 25, 2015 | 1:46 PM EDT

As health-care stocks rally, it's time for politicians to move on.

By

Chris Laudani

 | Jun 24, 2015 | 1:00 PM EDT

The biotech's stock has likely peaked, as increased competition awaits in the Hep-C space.

By

Jim Cramer

 | Jun 11, 2015 | 2:18 PM EDT

New companies are coming up with major drugs.

By

Jim Cramer

 | Jun 4, 2015 | 6:36 AM EDT

The dollar is weakening. That's actually good for stocks. 

By

Bret Jensen

 | May 27, 2015 | 12:00 PM EDT

Have it ready in case market turns volatile.

By

Jim Cramer

 | May 26, 2015 | 12:34 PM EDT

Jim Cramer reveals why his Action Alerts PLUS charitable trust portfolio is initiating coverage of Johnson & Johnson (JNJ) on Tuesday.

By

Jim Cramer

 | May 22, 2015 | 12:06 PM EDT

TheStreet's Jim Cramer answers your Twitter questions from the floor of the New York Stock Exchange.

By

Jim Cramer

 | May 15, 2015 | 3:11 PM EDT

With a weak dollar, calm oil and tame rates, we're doing fine.

By

Jim Cramer

 | May 14, 2015 | 4:04 PM EDT

Remember that rotations are vicious.

So, why did the markets really get pasted on Monday? I believe it had more to do with the...
Aetna (AET) is paying .8375 shares plus $125 cash for Humana (HUM). This along with Cigna ...
"Ain't no time to hate, barely time to wait, Wo, oh, what I want to know, where does the t...
Sorry folks. I received a few queries concerning my earlier note on IMF nullification of t...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.